Prestige Consumer Healthcare/$PBH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Prestige Consumer Healthcare
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
- Ticker
- $PBH
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 890
- Headquarters
- Tarrytown, United States
- Website
- www.prestigebrands.com
PBH Metrics
BasicAdvanced
$2.4B
13.91
$3.58
0.33
-
Price and volume
Market cap
$2.4B
Beta
0.33
52-week high
$71.07
52-week low
$42.62
Average daily volume
541K
Financial strength
Current ratio
3.23
Quick ratio
1.798
Long term debt to equity
1.066
Total debt to equity
1.077
Interest coverage (TTM)
6.36%
Profitability
EBITDA (TTM)
325.373
Gross margin (TTM)
54.77%
Net profit margin (TTM)
15.57%
Operating margin (TTM)
26.52%
Effective tax rate (TTM)
26.57%
Revenue per employee (TTM)
$1,240,000
Management effectiveness
Return on assets (TTM)
4.58%
Return on equity (TTM)
9.12%
Valuation
Price to earnings (TTM)
13.91
Price to revenue (TTM)
2.158
Price to book
1.23
Price to tangible book (TTM)
-1.19
Price to free cash flow (TTM)
10.132
Free cash flow yield (TTM)
9.87%
Free cash flow per share (TTM)
4.908
Growth
Revenue change (TTM)
-1.36%
Earnings per share change (TTM)
-16.09%
3-year revenue growth (CAGR)
-0.75%
10-year revenue growth (CAGR)
2.98%
3-year earnings per share growth (CAGR)
28.22%
10-year earnings per share growth (CAGR)
10.72%
What the Analysts think about PBH
Analyst ratings (Buy, Hold, Sell) for Prestige Consumer Healthcare stock.
Analyst projections of the future price of Prestige Consumer Healthcare stock.
Bulls say / Bears say
Fiscal first-quarter revenue rose 6.5%, with organic sales up 3.2%, while adjusted EPS increased year on year; the company said results beat expectations and reported strong growth in gastrointestinal and dermatological products. (Prestige Consumer Healthcare Inc.)
The acquisitions add recognised brands in new or complementary categories: Breathe Right is the leading nasal-strip brand, while LaCorium is a leader in Australian therapeutic skin care. Prestige sees scope to grow Breathe Right internationally and expand LaCorium through innovation and wider distribution. (GlobeNewswire, Prestige Consumer Healthcare Inc.)
Cash generation could help the company reduce the debt taken on for acquisitions: Prestige reported $83.7 million of adjusted free cash flow in the first quarter and expects about $900 million over the next three years. (Prestige Consumer Healthcare Inc., Prestige Consumer Healthcare Inc.)
Clear Eyes supply constraints have weighed on sales: fiscal 2026 revenue fell 4.3%, and the company says manufacturing and regulatory work could mean further shortages in sterile eye-care products. (Prestige Consumer Healthcare Inc., SEC)
Debt increased sharply to about $2.0 billion after the acquisitions, leaving Prestige reliant on strong cash generation to bring leverage down and increasing its financial risk if the integration or trading outlook disappoints. (SEC)
The higher fiscal 2027 revenue and adjusted EPS outlook reflects the acquired businesses, while the company kept its organic revenue growth forecast at only 1% to 3%; reported net income also fell to $29.2 million from $47.5 million in the first quarter. (Prestige Consumer Healthcare Inc.)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
PBH Financial Performance
Revenues and expenses
PBH Earnings Performance
Company profitability
Upcoming events
No upcoming events
PBH News
AllArticlesVideos
Funds containing PBH
AllUSDEURGBP
Fund name | Fund size | $PBH weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.13% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.13% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.08% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.